MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development

D. Chouhan, K. Browne, R. Patel, S. Karandikar, F. Laimo, D. Cullen, J. Duda (Philadelphia, USA)

Meeting: 2023 International Congress

Abstract Number: 1251

Keywords: Alpha-synuclein, Lewy bodies, Parkinson’s

Category: Parkinson's Disease: Pathophysiology

Objective: The objective of these studies is to develop a tissue engineered nigrostriatal system involving human dopaminergic and striatal cells to recapitulate many of the components of the nigrostriatal system for the study of pathophysiological mechanisms involved in the deposition of alpha-synuclein (a-syn), the role of axonal dystrophy and cell-to-cell transmission of a-syn.

Background: Parkinson’s disease (PD) motor deficits are caused by the loss of dopaminergic cells predominately located in the substantia nigra pars compacta and their long-projecting axonal tracts that innervate the striatum. Much is yet to be learned about the mechanisms of pathophysiology in PD including the role of a-syn aggregation, the relationship to neuritic dystrophy, and the role of cell-to-cell transmission of fibrillar a-syn.

Method: We have developed an in vitro model referred to as a tissue engineered nigrostriatal pathway (TE-NSP) using human induced dopaminergic neurons and striatal neurons, connected by long-projecting axonal pathways. TE-NSPs are built using a tubular hydrogel microcolumn (>1.5 cm long) comprised of an outer methacrylated hyaluronic acid (MeHA) encasement and an extracellular matrix (ECM) cocktail of collagen type I and laminin (1 mg/mL each) in the lumen. Cultured and aggregated dopaminergic and striatal neurons are seeded into either end of the micro-columns, with implantation conducted both sequentially, and simultaneously.

Results: Human-derived TE-NSPs were developed with bundled axonal tracts (> 12mm) from aggregated dopaminergic neurons projecting towards striatal neurons showing axonal-dendritic integration. We injected α-syn pre-formed fibrils (4 µM/mL) within the dopaminergic neuronal aggregates and show widespread uptake of a-syn, and neuronal survival (90-95% viability of both cell types) for at least 8 weeks. Immunocytochemistry confirmed α-syn aggregates within dopaminergic neurons and their axons which was associated with a down-regulation of tyrosine hydroxylase expression. In addition, a-syn aggregation was also demonstrated within the aggregated striatal neurons, confirming our system as a model for the axonal transport and cell-to-cell transmission of a-syn.

Conclusion: We have developed a tissue engineered construct that better represents some of the features of the nigrostriatal system in humans for investigating pathophysiology and therapeutic development.

To cite this abstract in AMA style:

D. Chouhan, K. Browne, R. Patel, S. Karandikar, F. Laimo, D. Cullen, J. Duda. A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/a-human-tissue-engineered-nigrostriatal-system-as-a-testbed-for-understanding-pd-pathophysiology-and-therapeutic-development/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/a-human-tissue-engineered-nigrostriatal-system-as-a-testbed-for-understanding-pd-pathophysiology-and-therapeutic-development/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley